574 related articles for article (PubMed ID: 23274199)
1. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
3. Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α.
Tomita S; Ishibashi K; Hashimoto K; Sugino T; Yanagida T; Kushida N; Shishido K; Aikawa K; Sato Y; Suzutani T; Yamaguchi O
Cancer Sci; 2011 Jan; 102(1):57-63. PubMed ID: 21054677
[TBL] [Abstract][Full Text] [Related]
4. Enhanced expression of suppresser of cytokine signaling 3 inhibits the IL-6-induced epithelial-to-mesenchymal transition and cholangiocarcinoma cell metastasis.
Zhou QX; Jiang XM; Wang ZD; Li CL; Cui YF
Med Oncol; 2015 Apr; 32(4):105. PubMed ID: 25744243
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
6. Suppressor of cytokine signalling-3 at pathological levels does not regulate lipopolysaccharide or interleukin-10 control of tumour necrosis factor-alpha production by human monocytes.
Prêle CM; Keith-Magee AL; Yerkovich ST; Murcha M; Hart PH
Immunology; 2006 Sep; 119(1):8-17. PubMed ID: 16925527
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of suppressor of cytokine signaling 3 on inflammatory cytokine expression and migration and proliferation of IL-6/IFN-γ-induced vascular smooth muscle cells.
Xiang S; Dong NG; Liu JP; Wang Y; Shi JW; Wei ZJ; Hu XJ; Gong L
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):615-622. PubMed ID: 24142708
[TBL] [Abstract][Full Text] [Related]
8. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
[TBL] [Abstract][Full Text] [Related]
9. SOCS3 modulates interleukin-6R signaling preference in dermal fibroblasts.
Luckett-Chastain LR; Ihnat MA; Mickle-Kawar BM; Gallucci RM
J Interferon Cytokine Res; 2012 May; 32(5):207-15. PubMed ID: 22313262
[TBL] [Abstract][Full Text] [Related]
10. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon.
Rigby RJ; Simmons JG; Greenhalgh CJ; Alexander WS; Lund PK
Oncogene; 2007 Jul; 26(33):4833-41. PubMed ID: 17297444
[TBL] [Abstract][Full Text] [Related]
11. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
[TBL] [Abstract][Full Text] [Related]
12. High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission.
Xu AT; Li Y; Zhao D; Shen J; Xu XT; Qiao YQ; Zhu MM; Wang TR; Cui Y; Ai LY; Ran ZH
Inflamm Bowel Dis; 2015 Feb; 21(2):241-50. PubMed ID: 25545374
[TBL] [Abstract][Full Text] [Related]
13. Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes.
Norkina O; Dolganiuc A; Catalano D; Kodys K; Mandrekar P; Syed A; Efros M; Szabo G
Alcohol Clin Exp Res; 2008 Sep; 32(9):1565-73. PubMed ID: 18616672
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells.
Souma Y; Nishida T; Serada S; Iwahori K; Takahashi T; Fujimoto M; Ripley B; Nakajima K; Miyazaki Y; Mori M; Doki Y; Sawa Y; Naka T
Int J Cancer; 2012 Sep; 131(6):1287-96. PubMed ID: 22095154
[TBL] [Abstract][Full Text] [Related]
15. Pien Tze Huang suppresses IL-6-inducible STAT3 activation in human colon carcinoma cells through induction of SOCS3.
Shen A; Chen Y; Hong F; Lin J; Wei L; Hong Z; Sferra TJ; Peng J
Oncol Rep; 2012 Dec; 28(6):2125-30. PubMed ID: 23027374
[TBL] [Abstract][Full Text] [Related]
16. STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P.
Horiguchi A; Oya M; Marumo K; Murai M
Kidney Int; 2002 Mar; 61(3):926-38. PubMed ID: 11849447
[TBL] [Abstract][Full Text] [Related]
17. Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells.
Usui E; Nishii K; Katayama N; Lorenzo V F; Chen F; Monma F; Otsuki T; Shiku H
Hematol J; 2004; 5(6):505-12. PubMed ID: 15570293
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
20. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
Tang Q; Jiang J; Liu J
Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
